Logo

PharmaShots Weekly Snapshots (April 11-15, 2022)

Share this
PharmaShots Weekly Snapshots (April 11-15, 2022)

PharmaShots Weekly Snapshots (April 11-15, 2022)

BMS and Nektar End Global Clinical Development Program for Bempegaldesleukin + Opdivo in Renal Cell Carcinoma and Bladder Cancer

Published: Apr 15, 2022 | Tags: BMS, Nektar, Bempegaldesleukin, Opdivo, Renal Cell Carcinoma, Bladder Cancer

SonoScape Receives the US FDA’s Approval for its Endoscopy System

Published: Apr 15, 2022 | Tags: SonoScape, US, FDA, Approval, Endoscopy System, HD-550

Boehringer Ingelheim and Autigen Collaborate to Discover and Develop Novel Treatments for Hearing Loss

Published: Apr 15, 2022 | Tags: Boehringer Ingelheim, Autigen, Collaborate, Discover, Develop, Novel Treatments, Hearing Loss

Valneva Received MHRA’s Conditional Marketing Authorization for its Inactivated COVID-19 Vaccine

Published: Apr 15, 2022 | Tags: Valneva, MHRA, Conditional Marketing Authorization, Inactivated COVID-19 Vaccine

Pfizer and BioNTech Seek Approval for Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Published: Apr 15, 2022 | Tags: Pfizer, BioNTech, Approval, Booster Dose, COVID-19 Vaccine, Children

Amneal Receives the US FDA’s Approval for Alymsys (biosimilar, bevacizumab)

Published: Apr 15, 2022 | Tags: Amneal, US, FDA, Almysys, biosimilar, Bevacizumab

Merck’s V116 Receives the US FDA’s Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia

Published: Apr 14, 2022 | Tags: Merck, V116, US, FDA, Breakthrough Therapy Designation, Invasive Pneumococcal Disease, Pneumococcal Pneumonia

CG Oncology Presents Interim Results of CG0070 + Keytruda (pembrolizumab) in P-II (CORE1) Study for NMIBC Unresponsive to Bacillus Calmette-Guerin at AACR 2022

Published: Apr 14, 2022 | Tags: CG Oncology, CG0070, Keytruda, pembrolizumab, P-II, CORE1 Study, NMIBC, Bacillus Calmette-Guerin, AACR, 2022

Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM

Published: Apr 14, 2022 | Tags: Sanofi, Rilzabrutinib, P-I/II Study, Immune Thrombocytopenia, NEJM

Halozyme Entered into a Definitive Agreement to Acquire Antares for ~$960M

Published: Apr 14, 2022 | Tags: Halozyme, Acquire, Antares, ~$960M

AbbVie and Genmab Report Results of Epcoritamab in P-I/II (EPCORE NHL-1) Trial for the Treatment of R/R Large B-cell Lymphoma

Published: Apr 14, 2022 | Tags: AbbVie, Genmab, Epcoritamab, P-I/II, EPCORE NHL-1 Trial, Large B-cell Lymphoma

Astellas’ Padcev (enfortumab vedotin) Receives EC’s Approval for the Treatment of Locally Advanced or Metastatic Urothelial Cancer

Published: Apr 14, 2022 | Tags: Astellas, Padcev, enfortumab vedotin, EC, Approval, Urothelial Cancer

LENZ Signs an Exclusive License Agreement with Ji Xing for LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) to Treat Presbyopia in Greater China

Published: Apr 13, 2022 | Tags: LENZ, Ji Xing, LNZ100, LNZ101, Presbyopia, Greater China

Apexigen Presents Results of Sotigalimab + Pembrolizumab in P-II Trial for the Treatment of Metastatic Melanoma at AACR 2022

Published: Apr 13, 2022 | Tags: Apexigen, Sotigalimab, Pembrolizumab, P-II Trial, Metastatic Melanoma, AACR, 2022

AbbVie Presents Results of Navitoclax + Ruxolitinib in P-II (REFINE) Trial for the Treatment of Myelofibrosis at AACR 2022

Published: Apr 13, 2022 | Tags: AbbVie, Navitoclax, Ruxolitinib, P-II, REFINE Trial, Myelofibrosis, AACR 2022

GSK to Acquire Sierra Oncology for ~$1.9B

Published: Apr 13, 2022 | Tags: GSK, Acquire, Sierra Oncology, ~$1.9B

Boehringer Ingelheim and Eli Lilly Receives the Health Canada Marketing Authorization for Jardiance (empagliflozin) to Treat HFpEF

Published: Apr 13, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Health Canada, Marketing Authorization, Jardiance, empagliflozin, HFpEF

Actinium Entered into a License and Supply Agreement with Immedica for Iomab-B (131I apamistamab) in EU and MENA Countries

Published: Apr 13, 2022 | Tags: Actinium, Immedica, Iomab-B, 131I apamistamab, EU, Middle East, North Africa

Takeda Reports Results of Takhzyro (lanadelumab) in P-III (SHP643-301/ SPRING) Study for the Treatment of Hereditary Angioedema

Published: Apr 12, 2022 | Tags: Takeda, Takhzyro, lanadelumab, P-III, SHP643-301, SPRING Study, Hereditary Angioedema

Engitix Expanded its 2020 Collaboration and License Agreement with Takeda to Develop New Anti-Fibrotic Therapies for Inflammatory Bowel Disease

Published: Apr 12, 2022 | Tags: Engitix, 2020, License Agreement, Takeda, Anti-Fibrotic Therapies, Inflammatory Bowel Disease

BMS Presents Results of Opdivo (nivolumab) in P-III (CheckMate-816) Trial as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer at AACR 2022

Published: Apr 12, 2022 | Tags: BMS, Opdivo, nivolumab, P-III, CheckMate-816 Trial, Resectable, Non-Small Cell Lung Cancer

Lilly Presents Results of Lebrikizumab in P-III (ADhere) Study for the Treatment of Atopic Dermatitis at RAD 2022

Published: Apr 12, 2022 | Tags: Lilly, Lebrikizumab, P-III, ADhere Study, Atopic Dermatitis, RAD, 2022

BioNTech Entered into an Exclusive Research Collaboration with Matinas BioPharma to Evaluate Novel Delivery Technology for mRNA-Based Vaccines

Published: Apr 12, 2022 | Tags: BioNTech, Matinas BioPharma, Technology, mRNA-Based Vaccines

Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan

Published: Apr 12, 2022 | Tags: Ardelyx, Amends, 2017, Agreement, Kyowa Kirin, Tenapanor, Hyperphosphatemia, Japan

Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at AACR 2022

Published: Apr 11, 2022 | Tags: Junshi, Coherus, Toripalimab, P-III, JUPITER-02 Study, Nasopharyngeal Carcinoma, AACR, 2022

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III (ALPINE) Trial for the Treatment of Chronic Lymphocytic Leukemia

Published: Apr 11, 2022 | Tags: BeiGene, Brukinsa, zanubrutinib, P-III, ALPINE Trial, Chronic Lymphocytic Leukemia

Gannex Reports First Patient Dosing in P-II Clinical Trial of ASC42 for the Treatment of Primary Biliary Cholangitis

Published: Apr 11, 2022 | Tags: Gannex, P-II, Clinical Trial, ASC42, Primary Biliary Cholangitis

Telix Entered into a Licence Agreement with Lilly to Develop and Commercialise Olaratumab for Cancer

Published: Apr 11, 2022 | Tags: Telix, Lilly, Olaratumab, Cancer

Amgen Presents Results of Lumakras (sotorasib) in P-I/II (CodeBreaK 100) Trial for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer at AACR 2022

Published: Apr 11, 2022 | Tags: Amgen, Lumakras, sotorasib, P-I/II, CodeBreaK 100 Trial, KRAS G12C-Mutated, Advanced, Non-Small Cell Lung Cancer, AACR 2022

Blueprint Presents Proof-of-Concept Data of BLU-945 in P-I/II (SYMPHONY) Trial for EGFR-Mutant Non-Small Cell Lung Cancer at AACR 2022

Published: Apr 11, 2022 | Tags: Blueprint, BLU-945, P-I/II, SYMPHONY Trial, EGFR-Mutant, Non-Small Cell Lung Cancer

 

Related Post: PharmaShots Weekly Snapshots (April 04-08, 2022)


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions